Monitor Epstein-Barr virus serology, development of infections during therapy. Oral forms are not interchangeable with other tacrolimus ext-rel products. Only physicians experienced in ...

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Tacrolimus 0.5mg, 1mg ... Monitor Epstein-Barr virus serology, development of infections during therapy. Risk of new onset diabetes after transplant (esp. Hispanic and black patients); monitor ...

He was readmitted 3 weeks later after further fits, despite anti-convulsant therapy. He was psychotic with visual hallucinations, and rapidly became obtunded. Although his tacrolimus blood ...

Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating ...

The dose-ranging trial has ultimately enrolled subjects across the tacrolimus’ 0.25mg ... including breakthrough therapy status. OLP is said to be a T-cell-mediated autoimmune condition leading to ...

The present study was conducted in a single center after selecting VKC patients refractory to conventional therapy in which topical tacrolimus was introduced to replace corticosteroids.

Overall, 6 out of 10 ciclosporin-treated patients and 5 out of 10 tacrolimus-treated patients maintained complete remission over the mean follow-up period of 23.0 ± 10.1 months after therapy ...

which were not controlled by the combination of anticonvulsants plus tacrolimus. The pathophysiological rationale underlying the use of a B-cell-depleting therapy, rituximab, was to suppress B ...

The post Lipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen Planus appeared first on PRISM MarketView.